


# Incidence of major adverse cardiac events following non-cardiac surgery

Lorraine Sazgary<sup>1†</sup>, Christian Puelacher <sup>(b)</sup> <sup>1</sup>\*<sup>†</sup>, Giovanna Lurati Buse<sup>2,3</sup>, Noemi Glarner<sup>1</sup>, Andreas Lampart<sup>3</sup>, Daniel Bolliger<sup>3</sup>, Luzius Steiner<sup>3</sup>, Lorenz Gürke<sup>4</sup>, Thomas Wolff<sup>4</sup>, Edin Mujagic<sup>4</sup>, Stefan Schaeren<sup>5</sup>, Didier Lardinois<sup>6</sup>, Jacqueline Espinola<sup>1,7</sup>, Christoph Kindler<sup>7</sup>, Angelika Hammerer-Lercher<sup>8</sup>, Ivo Strebel<sup>1</sup>, Karin Wildi<sup>1,3</sup>, Reka Hidvegi<sup>1</sup>, Johanna Gueckel<sup>1</sup>, Christina Hollenstein<sup>1</sup>, Tobias Breidthardt<sup>1,9</sup>, Katharina Rentsch<sup>10</sup>, Andreas Buser<sup>11</sup>, Danielle M. Gualandro<sup>1,12</sup>, and Christian Mueller <sup>(b)</sup> <sup>1</sup>; for the BASEL-PMI Investigators<sup>‡</sup>

<sup>1</sup>Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University Basel, Basel, Switzerland; <sup>2</sup>Department of Anesthesiology, University Hospital Dusseldorf, Moorenstraße 5, 40225 Düsseldorf, Germany ; <sup>3</sup>Department of Anesthesiology, University Hospital Basel, Spitalstrasse 21 4031 Basel, University of Basel, Basel, Switzerland; <sup>4</sup>Department of Vascular Surgery, University Hospital Basel, Spitalstrasse 21 4031 Basel, University of Basel, Basel, Switzerland; <sup>4</sup>Department of Vascular Surgery, University Hospital Basel, University of Basel, Basel, Switzerland; <sup>6</sup>Department of Traumatology & Orthopedics, Spitalstrasse 21 4031 Basel, University Hospital Basel, University of Basel, Basel, Switzerland; <sup>6</sup>Department of Thoracic Surgery, University Hospital Basel, Spitalstrasse 21 4031 Basel, University of Basel, Basel, Switzerland; <sup>7</sup>Department of Anesthesiology, Cantonal Hospital Aarau, Tellstrasse 25 5001 Aarau, Switzerland; <sup>8</sup>Department of Laboratory Medicine, Cantonal Hospital Aarau, Tellstrasse 25 5001 Aarau, Switzerland; <sup>9</sup>Department of Internal Medicine, University Hospital Basel, University Hospital Basel, University Hospital Basel, University Hospital Basel, Switzerland; <sup>11</sup>Bood Bank and Department of Hematology, University Hospital Basel, University of Basel, Petersgraben 4 4031 Basel, Switzerland; <sup>11</sup>Blood Bank and Department of Hematology, University Hospital Basel, University of Basel, Switzerland; and <sup>12</sup>Department of Cardiology, Incor, University of Sao Paulo, Av. Dr. Enéas Carvalho de Aguiar, 44 - Cerqueira César, São Paulo - SP, 05403-900 Sao Paulo, Brazil

Received 5 June 2020; revised 19 July 2020; editorial decision 30 July 2020; accepted 31 July 2020; online publish-ahead-of-print 14 October 2020

Aims	Major adverse cardiac events (MACE) triggered by non-cardiac surgery are prognostically important perioperative complications. However, due to often asymptomatic presentation, the incidence and timing of postoperative MACE are incompletely understood.
Methods and results	We conducted a prospective observational study implementing a perioperative screening for postoperative MACE [cardiovascular death (CVD), acute heart failure (AHF), haemodynamically relevant arrhythmias, spontaneous myo- cardial infarction (MI), and perioperative myocardial infarction/injury (PMI)] in patients at increased cardiovascular risk ( $\geq$ 65 years OR $\geq$ 45 years with history of cardiovascular disease) undergoing non-cardiac surgery at a tertiary hospital. All patients received serial measurements of cardiac troponin to detect asymptomatic MACE. Among 2265 patients (mean age 73 years, 43.4% women), the incidence of MACE was 15.2% within 30 days, and 20.6% within 365 days. CVD occurred in 1.2% [95% confidence interval (CI) 0.9–1.8] and in 3.7% (95% CI 3.0–4.5), haemodynamically relevant arrhythmias in 1.2% (95% CI 0.9–1.8) and in 2.1% (95% CI 1.6–2.8), AHF in 1.6% (95% CI 1.2–2.2) and in 4.2% (95% CI 3.4–5.1), spontaneous MI in 0.5% (95% CI 0.3–0.9) and in 1.6% (95% CI 1.2–2.2), and PMI in 13.2% (95% CI 11.9–14.7) and in 14.8% (95% CI 13.4–16.4) within 30 days and within 365 days, respect- ively. The MACE-incidence was increased above presumed baseline rate until Day 135 (95% CI 104–163), indicating a vulnerable period of 3–5 months.
Conclusion	One out of five high-risk patients undergoing non-cardiac surgery will develop one or more MACE within 365 days. The risk for MACE remains increased for about 5 months after non-cardiac surgery.



 $^{\dagger}$  The first two authors have contributed equally and should be considered first author.

<sup>&</sup>lt;sup>‡</sup> Additional BASEL-PMI investigators and contributors to this manuscript is listed in the ackowledegement section

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Trial registration	https://www.clinicaltrials.gov. Unique identifier: NCT02573532.		
Keywords	Acute myocardial infarction • Heart failure • Arrhythmia • Death • Surgery		

# Introduction

More than 300 million surgeries are performed worldwide per year.<sup>1</sup> Despite the undisputed benefits of surgery, surgical procedures are possible triggers for major adverse cardiac events (MACE), including myocardial infarction (MI)/injury, acute heart failure (AHF), haemodynamically relevant arrhythmias, and cardiovascular death (CVD).<sup>2-5</sup> Several complex pathophysiological processes triggered by the surgical and anaesthetic stress including an increase in sympathetic and neurohumoral activity, pro-coagulant factors, intravascular volume load, and systemic inflammation,<sup>6,7</sup> as well as several periprocedural factors such as intraoperative tachycardia,<sup>8</sup> intraoperative hypertension,<sup>9</sup> perioperative hypotension,<sup>8,10</sup> and perioperative anaemia,<sup>11</sup> seem to contribute to MACE following non-cardiac surgery. Especially perioperative myocardial infarction/injury (PMI) is increasingly recognized as major contributor to perioperative morality, yet often remains undetected as PMI most commonly present without typical symptoms of myocardial ischaemia such as chest pain, angina pectoris, or dyspnoea.<sup>2,12-14</sup> Therefore, PMI is often missed without systematic screening in clinical routine as well as observational research,<sup>2–15</sup> leading to an underestimation of incidence of perioperative MACE.

Furthermore, the time frame in which MACE are more frequent following non-cardiac surgery is unclear. Knowledge about the time window in which patients might require closer follow-up might facilitate the development of strategies for the prevention and early detection of MACE.<sup>16,17</sup>

In order to contribute to closing these major gaps in knowledge, we conducted a prospective study with a MACE screening programme embedded in clinical routine aiming to reliably estimate incidence of MACE following non-cardiac surgery and to define the postoperative period during which MACE rate is still increased by the surgical procedure.

# **Methods**

### Study design and patient population

We conducted a prospective cohort single-centre study (BASEL-PMI) including consecutive high-risk patients undergoing non-cardiac surgery at the University Hospital Basel, Switzerland between October 2014 and November 2015. Written general consent to registration in a dedicated prospective database was obtained from all individual participants included in the study after ethics approval (EKNZ 2015-301, NCT02573532) and in accordance with the ethical standards laid down in the Declaration of Helsinki. We adhered to the STROBE reporting guide-lines, with further information found in the Supplementary material online.

High-risk patients were defined as aged between 65 and 85 years OR between 45 to 64 years AND a history of cardiovascular disease

(coronary artery disease, peripheral artery disease, or stroke). Patients had elective, urgent, or emergency non-cardiac surgery and stayed in hospital at least one night after surgery. Non-cardiac surgery involved visceral, orthopaedic, trauma, vascular, urologic, spinal, and thoracic surgical procedures. We excluded patients who declined general consent, were incorrectly screened (<45 years, hospitalization <24 h, surgery involving the heart), had their surgery cancelled or were enrolled more than once within 1 year after surgery (Supplementary material online, *Figure S1*).

#### **Procedures and outcome adjudication**

#### **MACE** screening

Patients meeting the eligibility criteria received a cardiac troponin-based screening for PMI as well as MACE embedded in clinical routine. Patients were followed for 1 year to assess occurrence of CVD, AHF, haemodynamically relevant arrhythmias, spontaneous MI, and PMI.<sup>14</sup> CVD included death attributable to MI, sudden cardiac death, AHF, stroke, cardiovascular procedure, cardiovascular haemorrhage (e.g. ruptured aortic aneurysm or dissection), and pulmonary embolism.<sup>14</sup> AHF was defined as AHF requiring admission to the hospital or the in-hospital transfer to an intensive care unit or the use of intravenous diuretics. Haemodynamically relevant arrhythmias were defined as cardiac arrest, sustained ventricular tachycardia, atrial fibrillation with the need of treatment (electrical or chemical cardioversion, or a heart rate >120 b.p.m. with the need of rate control such as beta-blockers or calcium channel blockers), and atrioventricular block III. Spontaneous MI was defined according to the universal definition of MI.<sup>18,19</sup> In order to differentiate between PMI vs. pre-existing elevations of high-sensitivity cardiac troponin T (hs-cTnT) due to chronic or even acute cardiac disorders, the routine screening consisted of a preoperative hs-cTnT measurement as baseline concentration, and two postoperative measurements on postoperative Days 1 and 2.14,20 In case of a PMI, defined as an absolute increase in hs-cTnT concentrations of  $\geq 14$  ng/L above preoperative concentrations, or between two postoperative concentrations, if the preoperative concentration was missing,<sup>14</sup> a study physician prospectively recorded patient symptoms and a 12-lead electrocardiogram. Additionally, a cardiology consultation was triggered. PMI were also recorded during subsequent operations. If deemed indicated clinically, further measurements of hs-cTnT were made.

#### Follow-up

Patients and family physicians were contacted 365 days after the surgical procedure by mail or telephone calls. In addition, electronic health records of the University Hospital Basel and all other institutions mentioned during follow-up were reviewed for MACE. Moreover, the national registry on mortality was reviewed for all patients.

### Aims

The primary aim was to define the 30-day and 365-day incidence of MACE. The secondary aim was to define the postoperative period during which the MACE rate is still increased by the surgical procedure.

# Statistical analysis

Continuous variables were expressed as medians and interquartile ranges, categorical variables as numbers and percentages. The Mann–Whitney U test was used to compare continuous variables, and the Fisher's exact test for categorical variables. The 30-day and 365-day incidence of the combined endpoint MACE were calculated as the amount of patients suffering at least one MACE with the associated 95% confidence interval (95% Cl). The 30-day incidence of MACE was stratified by surgical discipline and European Society of Cardiology/European Society of Anesthesiology (ESC/ESA) surgical risk.<sup>21</sup>

Time to first MACE, and the univariable association between PMI and the occurrence of further MACE during 365 days of follow-up were shown by Kaplan–Meier Curves. Differences were assessed using the logrank test. Total number of events, with multiple events allowed per patient, was calculated because total MACE even better reflects total harm and total costs from a societal perspective.

To determine the postoperative period during which the MACE rate is still increased by the surgical procedure, we investigated the time of occurrence of MACE within the follow-up period of 365 days for our patient cohort. We constructed a model with days after surgery on the *x*axis, and pending MACE on the *y*-axis. We investigated changes in the slope of the curve, and assumed that after postoperative Day 300 the MACE rate in so longer affected by the surgical procedure, referring to a large observational study of intermediate to high-risk vascular surgery patients.<sup>22</sup> By comparison of the slope of piece-wise linear regression of pending MACE, a change in trend in MACE rate was estimated. We performed this analysis for the entire patient cohort, and for the subgroup of patients with initial PMI, and without initial PMI.

All hypothesis testing was two-tailed, and *P*-values of <0.05 were considered to be statistically significant. IBM SPSS Statistics, version 22.0, and R Studio, version 3.4.1, were used to perform all statistical analyses.

# Results

### **Baseline characteristics**

The patient flow is shown in Supplementary material online, Figure S1. Baseline characteristics of the 2265 patients eligible for the 30-day analysis are presented in *Table 1*. Briefly, median age was 73 years and 43.3% (984/2265) of patients were women. Patients developing MACE were older, more often had a history of cardiac disease, cardiovascular risk factors, and chronic kidney disease, and more often underwent emergency surgery. Moreover, the incidence of MACE differed according to surgical specialty.

### Incidence of MACE

Follow-up was complete at 365 days in 99.5% of patients. Preoperative measurements of hs-cTnT were available in 2116 of 2265 patients (93.4%).

At least one MACE occurred in 344/2265 patients (15.2%; 95% CI 13.8–16.8%) within 30 days (*Table 2*) and in 466/2265 patients (20.6%; 95% CI 19–22.3%) within 365 days after the surgical procedure (*Figure 1A*). CVD occurred in 1.2% (95% CI 0.9–1.8) and in 3.7% (95% CI 3.0–4.5), haemodynamically relevant arrhythmias in 1.2% (95% CI 0.9–1.8) and in 2.1% (95% CI 1.6–2.8), AHF in 1.6% (95% CI 1.2–2.2) and in 4.2% (95% CI 3.4–5.1), spontaneous MI in 0.5% (95% CI 0.3–0.9) and in 1.6% (95% CI 1.2–2.2), and PMI in 13.2% (95% CI 0.3–0.9)

11.9–14.7) and in 14.8% (95% Cl 13.4–16.4), within 30 and 365 days, respectively (*Table 2*).

In total, with multiple events allowed per patient, within 7 days after the surgical procedure 363 events and from postoperative Day 8 until Day 365, 403 events were recorded, resulting in a total MACE number of 766 events in 2265 patients (Supplementary material online, Figure S2). Within the first 7 postoperative days 47.4% (95% CI 43.9–50.9), and within the first 30 days after surgery 62.5% (95% CI 59.1-65.9) of the total event rate were recorded. For each single component of MACE, the proportion out of the total event rate was as followed: for CVD 1.3% (95% CI 0.7-2.4) and 3.7% (95% CI 2.5-5.2), for haemodynamically relevant arrhythmias 4.3% (95% CI 3.1-6.0) and 7.3% (95% CI 5.7-9.4), for AHF 4.4% (95% CI 3.2-6.1) and 8.1% (95% CI 6.4-10.2), for spontaneous MI 0.7% (95% CI 0.3-1.5) and 1.6% (95% CI 0.9-2.7), and for PMI 36.7% (95% CI 33.4-40.2) and 41.9% (95% Cl 38.5-45.4) within 7 days and within 30 days after surgery respectively. The absolute numbers are presented in Supplementary material online, Figure S2.

The incidence of MACE increased with higher ESC/ESA surgical risk category, ranging from 6% (95% CI 2–15%) in the lowest (<1% risk) to 57% (95% CI 25–84) in the highest (>5% risk) category. The 30-day MACE incidence varied among different types of surgery. The highest 30-day incidence was observed in thoracic surgery patients with 22% (95% CI 17–29), followed by vascular and trauma surgery patients with 21% (95% CI 17–26) and 19% (95% CI 15–23), respectively (Supplementary material online, *Table S1*).

# Association of PMI with other MACE occurring within 365 days

Within 365 days, 90/274 patients with PMI (32.9%; 95% CI 27.6– 38.6) suffered from at least one further MACE, compared to 190/1989 patients without PMI (9.6%; 95% CI 8.3–10.9) (*Figure 1B*). Of all 445 events occurring after Day 3, 128 events (28.8%) occurred in patients with initial PMI. Furthermore, CVD, haemodynamically relevant arrhythmias, AHF, and spontaneous MI occurred significantly more frequent in patients with initial PMI as compared to patients without initial PMI (Figure 2A–D).

### Time to MACE

The time of occurrence of MACE within the follow-up period of 365 days for our entire patient cohort is shown in *Figure 3*. The rapid drop in the curve within the first postoperative days is mainly related to PMI detected during the perioperative hs-cTnT-screening period. Following this, a change in trend is seen at Day 135 (95% CI 104–163), with a steeper slope from Day 0–103 vs. Day 164–365. From this, we concluded that the occurrence of MACE is more frequent within the first 3–5 months after surgical procedure. The MACE risk is highest within the first 30 days after surgery and in particular high within the first 7 days after surgery (*Figure 3*, Supplementary material online, *Figure S2*).

When applying the same analysis for the subgroup of patients with initial PMI (n = 275), and for the subgroup of patients without initial

	Overall (n = 2265; 100%)	No 30-day MACE (n = 1921; 84.8%)	30-day MACE (n = 344; 15.2%)	p-value
Age (years)	73 (68–79)	73 (68–79)	77 (70–82)	<0.001
Sex, male	1281 (56.6)	1086 (56.7)	192 (55.8)	0.77
Medical history				
Coronary artery disease	621 (27.4)	489 (25.5)	132 (38.4)	<0.001
Prior myocardial infarction	303 (13.4)	230 (12.0)	73 (21.2)	<0.001
Congestive heart failure	244 (10.9)	177 (9.2)	67 (20.7)	<0.001
Atrial fibrillation	340 (15.0)	251 (13.1)	89 (25.9)	<0.001
Valvular heart disease	249 (11.0)	180 (9.4)	69 (20.1)	<0.001
Peripheral artery disease	385 (17.0)	298 (15.5)	87 (25.3)	<0.001
Prior stroke	210 (9.3)	173 (9.0)	37 (10.8)	0.31
Hypertension	1453 (64.2)	1209 (62.9)	244 (70.9)	0.005
Diabetes mellitus	521 (23.0)	410 (21.3)	111 (32.3)	<0.001
Chronic kidney disease (CKD $\geq$ III)	330 (14.6)	236 (12.3)	94 (27.3)	<0.001
Active cancer	568 (25.1)	501 (26.1)	67 (19.5)	0.008
Type of surgery				<0.001
Elective surgery	1492 (65.9)	1306 (68.0)	186 (54.13)	
Urgent surgery (>24 h)	339 (15.0)	265 (13.8)	74(21.5)	
Emergency surgery (≤24 h)	434 (19.2)	350 (18.2)	84 (24.4)	
Surgical speciality				<0.001
Orthopaedic	262 (11.6)	219 (11.4)	43 (12.5)	
Trauma	417 (18.4)	338 (17.6)	79 (23.0)	
Spinal	355 (15.7)	309 (16.1)	46 (13.4)	
Thoracic	192 (8.5)	149 (7.8)	43 (12.5)	
Urologic	358 (15.8)	327 (17.0)	31 (9.0)	
Vascular	279 (12.3)	220 (11.5)	59 (17.2)	
Visceral	316 (14.0)	286 (14.9)	30 (8.7)	
Other	86 (3.8)	73 (3.8)	13 (3.8)	

# Table I Baseline characteristics shown for all patients and classified according to the occurrence of MACE within 30 days after surgery

Continuous variables are presented as medians (1st and 3rd quartile), categorical variables are presented as numbers (%). Continuous variables were compared with the Mann-Whitney *U* test, and categorical variables with the Fisher's exact test.

CKD-EPI, chronic kidney disease-epidemiology collaboration; MACE, major adverse cardiac events.

# Table 2 30-day and 365-day incidences shown for the combined endpoint MACE with its single components, and for the secondary endpoint, all-cause mortality

	30-day incidence (95% CI)	365-day incidence (95% CI)
Combined endpoint MACE	15.2% (13.8–16.8) (344/2265)	20.6% (19.0–22.3) (466/2265)
Cardiovascular death	1.2% (0.9–1.8) (28/2265)	3.7% (3.0–4.5) (83/2265)
Haemodynamically-relevant arrhythmias	1.2% (0.9–1.8) (28/2265)	2.1% (1.6–2.8) (47/2265)
Acute heart failure	1.6% (1.2–2.2) (36/2265)	4.2% (3.4–5.1) (95/2265)
Perioperative myocardial infarction/injury <sup>a</sup>	13.2% (11.9–14.7) (300/2265)	14.8% (13.4–16.4) (336/2265)
Spontaneous myocardial infarction	0.5% (0.3–0.9) (12/2265)	1.6% (1.2–2.2) (37/2265)
Secondary endpoint		
All-cause mortality	3.0% (2.3–3.7) (67/2265)	11.5% (10.3–12.9) (261/2265)

Data are presented as percentage (95% confidence interval), in brackets () absolute number/total number of patients.

CI, confidence interval; MACE, major adverse cardiac events.

<sup>a</sup>Initial PMI and PMI occurring during subsequent surgical procedures within 365 days of follow-up.

553

Δ в 0.4 Cumulative incidence of MACE 0.3 0.3 p<0.001 Cumulative incidence of MACE 0.2 0.2 0.1 0.1 0.0 90 180 270 360 Days to MACE 0.0 90 180 270 360 194 1813 90 Days to MACE 179 760 180 81 837 360 2233 837

Figure I Cumulative incidence of MACE within 365 days of follow-up. Kaplan-Meier curves displaying the cumulative incidence of MACE within 365 days of follow-up for (A) all patients (n = 2265, 464 events), and (B) split for patients with PMI (n = 274 with 90 events in red), and without PMI (n = 1989 with 190 events in green). Differences between groups (with, and without PMI) were assessed using the log-rank test. MACE, major adverse cardiac events; PMI, perioperative myocardial injury/infarction.

PMI (n = 1990), the change in trend is seen at postoperative Day 142 (95% CI 55-209), and postoperative Day 130 (95% CI 94-162), respectively, with no significant difference between groups (Supplementary material online, Figure S3 and Table S2).

## Discussion

This prospective cohort study enrolling consecutive patients at increased cardiovascular risk undergoing non-cardiac surgery screened for perioperative MACE. We report three major findings:

First, the incidence of MACE was high. CVD occurred in 1.2%, haemodynamically relevant arrhythmias in 1.2%, AHF in 1.6%, and spontaneous MI in 0.5% of patients. Including also the emerging entity of PMI, one out of seven patients developed at least one MACE within 30 days. The MACE rate, particularly AHF and PMI, was much higher than expected and reported in previous studies, that did not systematically screen for MACE.<sup>4,5,23</sup> Other components of MACE less affected by ascertainment bias including all-cause mortality had similar incidence as compared to previous studies<sup>2,5,12,24,25</sup> which supports the generalizability of our findings. In other recent screening studies also including younger low-risk patients<sup>12,26,27</sup> at 30 days the rate of cardiovascular mortality was 1.2%<sup>27</sup> and 1.9%,<sup>12</sup> MI 4.2%, AHF 0.9%, and clinically relevant atrial fibrillation 1,6%.<sup>25</sup> In POISE-2, death or MI occurred in 11.8% of patients at 365 days.<sup>28</sup>

The incidence of MACE varied among different types of surgery. The 30-day MACE incidence was highest in thoracic surgery patients with 22%, followed by vascular surgery with 21%. This extends and corroborates findings of a recently published observational study including cardiovascular high-risk patients undergoing elective thoracic surgery.<sup>3</sup> The extent of lung resection was identified as an independent risk factor for developing myocardial injury, which suggests that mechanism like systemic inflammatory processes or an elevation of the right ventricular afterload might have an impact on perioperative cardiovascular outcomes in thoracic surgery patients.<sup>3</sup> Additionally to the specific surgical procedure performed, there

seem to be several other factors effecting cardiovascular outcomes, such as the obesity paradox<sup>13,29</sup> or preoperative anaemia,<sup>30</sup> which was identified as a strong predictor for cardiac events in vascular surgery patients.<sup>16</sup>

Second, patients with PMI, of which the majority did not experience symptoms during the event due to accompanying anaesthesia, are not only at increased risk of death within 1  $year^{14,31,32}$  but also at increased risk of future AHF, haemodynamically relevant arrhythmias, and spontaneous MI. This extends and corroborates important studies showing that postoperative myocardial ischaemia detected within the first 48 h after non-cardiac surgery by continuous electrocardiographic monitoring was independently associated with an increased risk of adverse cardiac events,<sup>33</sup> and 70% of all adverse cardiac events were preceded by postoperative ischaemia.<sup>2,4</sup> Considering our findings, a MACE Screening using hs-cTnT measurements preoperatively and on postoperative Day 1 and 2 for patients meeting the high-risk criteria used in this study might provide an opportunity to improve perioperative care.


Third, we report that the vulnerable period after non-cardiac surgery with increased risk of MACE lasts about 5 months, and is similar in length in patients with vs. without initial PMI. A recently published large international, randomized, placebo-controlled trial supports this concept.<sup>34</sup> Similarly, in a large observational study of intermediate- or high-risk vascular surgery patients, the hazard of mortality was greatest in the first months and persisted up to 10 months after surgery.<sup>22</sup> Our findings show that the MACE risk is especially high within the first 30 days after surgery, and in particular within the first postoperative 7 days, which has important clinical implications when considering the optimal length of therapeutic interventions aimed at reducing the MACE rate after non-cardiac surgery. Furthermore, this finding should inform the design of future clinical trials aimed at preventing MACE after non-cardiac surgery.

### **Strengths**

To the best of our knowledge, this is the first prospective study investigating long-term MACE after non-cardiac surgery in consecutive







**Figure 2** Cumulative incidence of the single components of MACE within 365 days of follow-up split for patients with and without PMI. Kaplan–Meier curves showing the cumulative incidence of the single components of MACE for (A) CVD (with PMI: n = 275, 23 events; without PMI: n = 1990; 60 events). (B) Haemodynamically relevant arrhythmias (with PMI: n = 274, 19 events; without PMI: n = 1989, 26 events). (C) AHF (with PMI: n = 275, 31 events; without PMI: n = 1990, 64 events). (D) Spontaneous MI (with PMI: n = 275; 9 events; without PMI: n = 1990, 28 events). Each split for patients with PMI (red line) and without PMI (green line). Differences between groups (with, and without PMI) were assessed using the log-rank test. Patients with initial PMI are more likely to suffer from CVD, haemodynamically relevant arrhythmias, AHF, and spontaneous MI during 365 days of follow-up. AHF, acute heart failure; CVD, cardiovascular death; MACE, major adverse cardiac events; MI, myocardial infarction; PMI, perioperative myocardial injury/infarction.

patients incorporating systematic screening for PMI and AHF. The large sample size of 2265 patients, central adjudication of MACE, 365 days follow-up and very high completeness of long-term follow-up with 99.5% (95% CI 99.2–99.7%) are important additional strengths.


### Limitations

Several limitations should be considered when interpreting these findings. *First*, this was a single-centre study. As the 30-day rate of AHF, haemodynamically relevant arrhythmias, and CVD was comparable to that observed in the international VISION study<sup>12,25,27</sup> our main findings likely also apply to most other institutions. Still, future studies need to externally validate the point estimates for the different MACE components derived in this study. *Second*, until now controversies exist regarding the definition of PMI.<sup>13,14,35</sup> Changes in the definition of PMI will invariably also affect overall MACE rate.<sup>3,12,26,27,36</sup> *Third*, although using a very stringent methodology to

detect and adjudicate MACE, we likely still have underestimated the MACE rate as the screening for PMI was performed only on the first and second postoperative day. *Fourth*, in the absence of a fully-matched control population with comparable cardiac and non-cardiac comorbidities, but not undergoing surgery, the quantification of the vulnerable period after non-cardiac surgery required assumptions and should therefore be considered a range rather than a precise point-estimate. It definitely requires external validation in future studies.

# Conclusion

One out of five high-risk patients undergoing non-cardiac surgery will develop one or more MACE within 365 days. The risk for MACE remains increased for about 5 months after non-cardiac surgery.



**Figure 3** Time of occurrence of MACE within 365 days of follow-up. The time of occurrence of MACE within 365 days of follow-up shown for the entire patient cohort (n = 2265). Days after surgery on the *x*-axis, and pending events (in percent) on the *y*-axis. The green line was derived by linear regression of pending events from postoperative Day 300 to 365, the red line was derived by linear regression of pending events from postoperative Day 300 to 365, the red line was derived by linear regression of pending events from postoperative Day 300 to 365, the red line was derived by linear regression of pending events from postoperative Day 300 to 365, the red line was derived by linear regression of pending events from postoperative Day 300 to 365, the red line was derived by linear regression of pending events from postoperative Day 300 to 118. 95% CI. The intersection area is at 135 (95% CI 104–163) days of follow-up and is also shown by the orange coloured bar below with the label 'Change in trend'. The steeper slope from postoperative Day 0 to 103 is illustrated by the red coloured bar with the label 'MACE rate affected by the surgical procedure', and the time period from postoperative Day 164 to 365 is illustrated by the green coloured bar with the label 'stable event rate'. MACE, major adverse cardiac events.

As this incidence is much higher than commonly expected, novel strategies to reduce cardiac complications seem warranted.

# Supplementary material

Supplementary material is available at European Heart Journal: Acute Cardiovascular Care online.

### Acknowledgements

We wish to thank the patients who participated in this study, as well as the clinical teams caring for them.

# Additional BASEL-PMI investigators and contributors to this manuscript

Stella Marbot<sup>1</sup>, Joan Walter<sup>1</sup>, Michael Freese<sup>1</sup>, Thomas Nestelberger<sup>1</sup>, Jasper Boeddinghaus<sup>1</sup>, Jeanne du Fay de Lavallaz<sup>1</sup>, Raphael Twerenbold<sup>1</sup>, Patrick Badertscher<sup>1</sup>, Luca Koechlin<sup>1</sup>, Tobias Zimmermann<sup>1</sup>, Valentina Troester<sup>1</sup>, Eleni Michou<sup>1</sup>, Stefan Osswald<sup>1</sup>,

Esther Seeberger, MD<sup>1</sup>; Manfred Seeberger, MD<sup>2</sup>; Daniel Rickli<sup>3</sup>; Desiree Wussler, MD<sup>1</sup>; Julia Dinort, MD<sup>1</sup>; Alexandra Prepoudis, MD<sup>1</sup>; Kathrin Meissner, RN<sup>1</sup>; Gregor Fahrni, MD<sup>1</sup>; Raban Jeger, MD<sup>1</sup>; Christoph Kaiser, MD<sup>1</sup>; Laura Infanti, MD<sup>4</sup>

<sup>1</sup>Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University Basel, Basel, Switzerland; <sup>2</sup>Department of Anaesthesiology, Hirslanden Clinic, Witellikerstrasse 40, 8032 Zürich, Switzerland <sup>3</sup>Department of Traumatology & Orthopedics, University Hospital Basel, University of Basel, Basel, Switzerland <sup>4</sup>Blood Bank and Department of Hematology, University Hospital Basel, University Basel, Basel, Switzerland

### Funding

This study was funded by the University Basel, the University Hospital Basel, the Swiss Heart Foundation, the Swiss National Science Foundation, Abbott, Astra Zeneca, Roche, the PhD Educational Platform for Health Sciences, the Forschungsfond Kantonsspital Aarau, and the Cardiovascular Research Foundation Basel. The funders had no role in the design, data collection, statistical analysis, writing of this manuscript, or decision to publish.

# **Consent to participate**

Written general consent to registration in a dedicated prospective database was obtained from all individual participants included in the study.

Conflict of interest: Dr. Puelacher reports grants from PhD Educational Platform for Health Sciences, Roche Diagnostics and the University Hospital Basel as well as chaired an advisory board for Roche Diagnostics, during the conduct of the study. Dr. Gualandro has received research grants from FAPESP (Sao Paulo Research Foundation) for the submitted work, and speaker or consulting honoraria from Servier and Roche, outside the submitted work. Dr. Lurati Buse reports grants from University of Basel as well as cochaired an advisory board for Roche Diagnostics, during the conduct of the study. Dr. Hammerer-Lercher reports speaker or consulting honoraria from Roche, Abbott and Beckman, outside the submitted work. Dr. Kindler reports grants from Forschungsfond Kantonsspital Aarau, during the conduct of the study. Dr. Mueller reports grants from the Swiss Heart Foundation and grants and nonfinancial support from several diagnostic companies during the conduct of the study, as well as grants, personal fees and non-financial support from several diagnostic companies outside the submitted work. All other authors report no conflicts of interest.

### References

- Weiser TG, Haynes AB, Molina G, Lipsitz SR, Esquivel MM, Uribe-Leitz T, Fu R, Azad T, Chao TE, Berry WR, Gawande AA. Estimate of the global volume of surgery in 2012: an assessment supporting improved health outcomes. *Lancet* 2015;**385**:S11.
- Devereaux PJ, Xavier D, Pogue J, Guyatt G, Sigamani A, Garutti I, Leslie K, Rao-Melacini P, Chrolavicius S, Yang H, Macdonald C, Avezum A, Lanthier L, Hu W, Yusuf S. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med 2011;**154**:523–528.
- González-Tallada A, Borrell-Vega J, Coronado C, Morales P, Miguel M de, Ferreira-González I, Nadal M de. Myocardial injury after noncardiac surgery: incidence, predictive factors, and outcome in high-risk patients undergoing thoracic surgery: an observational study. J Cardiothorac Vasc Anesth 2019;34:426–432.
- Mangano DT, Browner WS, Hollenberg M, Li J, Tateo IM. Long-term cardiac prognosis following noncardiac surgery. The Study of Perioperative Ischemia Research Group. JAMA 1992;268:233–239.
- 5. Sabaté S, Mases A, Guilera N, Canet J, Castillo J, Orrego C, Sabaté A, Fita G, Parramón F, Paniagua P, Rodríguez A, Sabaté M, ANESCARDIOCAT Group B, Rivilla M, Gine M, Sadurni M, Fau M, Arroyo R, Rojo A, Pujol Rosa E, Rovira I, Alcon A, Lacambra M, Pi A, Campello D, Sierra P, Arnal A, Llorente C, Mazo V, Lopez S. Incidence and predictors of major perioperative adverse cardiac and cerebrovascular events in non-cardiac surgery. *Br J Anaesth* 2011;**107**:879–890.
- Kehlet H. The modifying effect of anesthetic technique on the metabolic and endocrine responses to anesthesia and surgery. *Acta Anaesthesiol Belg* 1988;39: 143–146.
- Gualandro DM, Campos CA, Calderaro D, Yu PC, Marques AC, Pastana AF, Lemos PA, Caramelli B. Coronary plaque rupture in patients with myocardial infarction after noncardiac surgery: frequent and dangerous. *Atherosclerosis* 2012; 222:191–195.
- Abbott TEF, Pearse RM, Archbold RA, Ahmad T, Niebrzegowska E, Wragg A, Rodseth RN, Devereaux PJ, Ackland GL. A prospective international multicentre cohort study of intraoperative heart rate and systolic blood pressure and myocardial injury after noncardiac surgery: Results of the VISION study. *Anesth Analg* 2018;**126**:1936–1945.
- 9. Reich DL, Bennett-Guerrero E, Bodian CA, Hossain S, Winfree W, Krol M. Intraoperative tachycardia and hypertension are independently associated with

adverse outcome in noncardiac surgery of long duration. Anesth Analg 2002;**95**: 273–277, table of contents.

- Roshanov PS, Sheth T, Duceppe E, Tandon V, Bessissow A, Chan MTV, Butler C, Chow BJW, Khan JS, Devereaux PJ. Relationship between perioperative hypotension and perioperative cardiovascular events in patients with coronary artery disease undergoing major noncardiac surgery. *Anesthesiology* 2019;**130**:756–766.
- Dunne JR, Malone D, Tracy JK, Gannon C, Napolitano LM. Perioperative anemia: an independent risk factor for infection, mortality, and resource utilization in surgery. J Surg Res 2002;102:237–244.
- Devereaux PJ, Chan MT V, Alonso-Coello P, Walsh M, Berwanger O, Villar JC, Wang CY, Garutti RI, Jacka MJ, Sigamani A, Srinathan S, Biccard BM, Chow CK, Abraham V, Tiboni M, Pettit S, Szczeklik W, Lurati Buse G, Botto F, Guyatt G, Heels-Ansdell D, Sessler DI, Thorlund K, Garg AX, Mrkobrada M, Thomas S, Rodseth RN, Pearse RM, Thabane L, McQueen MJ. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA 2012;307:2295–2304.
- Hidvegi R, Puelacher C, Gualandro DM, Lampart A, Lurati Buse G, Hammerer-Lerchner A, Walter J, Liffert M, Bolliger D, Steiner L, Kindler C, Espinola J, Strebel I, Gueckel J, Marbot S, Arslani K, Boeddinghaus J, Nestelberger T, Zimmermann T, Freese M, Guerke L, Mujagic E, Rikli D, Buser A, Mueller C, Wolff T, Wildi K, Genini A, Twerenbold R, Sazgary L. Obesity paradox and perioperative myocardial infarction/injury in non-cardiac surgery. *Clin Res Cardiol* 2020;doi:10.1007/s00392-020-01605-0.
- 14. Puelacher C, Lurati Buse G, Seeberger D, Sazgary L, Marbot S, Lampart A, Espinola J, Kindler C, Hammerer A, Seeberger E, Strebel I, Wildi K, Twerenbold R, Fay de Lavallaz J du, Steiner L, Gurke L, Breidthardt T, Rentsch K, Buser A, Gualandro DM, Osswald S, Mueller C. Perioperative myocardial injury after noncardiac surgery. *Circulation* 2018;**137**:1221–1232.
- 15. Pearse R, Moreno RP, Bauer P, Pelosi P, Metnitz P, Spies C, Vallet B, Vincent JL, Hoeft A, Rhodes A, Fagnoul D, Obbergh L van, Al-Subaie N, Arif F, Cashman J, Cecconi M, Edsell M, Fossati N, Hammond SJ, Hamilton M, Lonsdale D, Moran C, Rhodes A, Siegmueller C, Velzeboer F, Wong P, Awlakpui E, Scheidemann M, Wittmann M, Damster S. Mortality after surgery in Europe: a 7 day cohort study. *Lancet* 2012;**380**:1059–1065.
- Gualandro DM, Puelacher C, LuratiBuse G, Llobet GBGB, Yu PCPC, Cardozo FA, Glarner N, Zimmerli A, Espinola J, Corbière S, Calderaro D, Marques ACAC, Casella IBIB, Luccia N de, Oliveira MTMT, Lampart A, Bolliger D, Steiner L, Seeberger M, Kindler C, Osswald S, Gürke L, Caramelli B, Mueller C, GREAT network. Prediction of major cardiac events after vascular surgery. J Vasc Surg 2017;66:1826–1835.e1.
- Duceppe E, Parlow J, MacDonald P, Lyons K, McMullen M, Srinathan S, Graham M, Tandon V, Styles K, Bessissow A, Sessler DI, Bryson G, Devereaux PJ. Canadian Cardiovascular Society Guidelines on perioperative cardiac risk assessment and management for patients who undergo noncardiac surgery. *Can J Cardiol* 2017;**33**:17–32.
- Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. *Glob Heart* 2012;**7**:275–295.
- Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 2016; 37:267–315.
- Gualandro DM, Puelacher C, Mueller C. High-sensitivity cardiac troponin in acute conditions. *Curr Opin Crit Care* 2014;**20**:472–477.
- 21. Kristensen SD, Knuuti J, Saraste A, Anker S, Bøtker HE, Hert S De, Ford I, Juanatey JRG, Gorenek B, Heyndrickx GR, Hoeft A, Huber K, lung B, Kjeldsen KP, Longrois D, Luescher TF, Pierard L, Pocock S, Price S, Roffi M, Sirnes PA, Uva MS, Voudris V, Funck-Brentano C. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol 2014;**31**:517–573.
- Reed GW, Horr S, Young L, Clevenger J, Malik U, Ellis SG, Michael Lincoff A, Nissen SE, Menon V. Associations between cardiac troponin, mechanism of myocardial injury, and long-term mortality after noncardiac vascular surgery. J Am Heart Assoc 2017;6:e005672.
- Helwani MA, Amin A, Lavigne P, Rao S, Oesterreich S, Samaha E, Brown JC, Nagele P. Etiology of acute coronary syndrome after noncardiac surgery. *Anesthesiology* 2018;**128**:1084–1091.
- 24. Van Waes JAR, Grobben RB, Nathoe HM, Kemperman H, Borst GJ De, Peelen LM, Klei WA Van. One-year mortality, causes of death, and cardiac interventions in patients with postoperative myocardial injury. *Anesth Analg* 2016;doi: 10.1213/ANE.00000000001313.

- 25. Bhandari M, Buckley N, Cinà CS, Cook DJ, Beer J de, Devereaux PJ, Guyatt GH, Haynes RB, Heels-Ansdell D, Julian JA, Marcaccio M, Mrkobrada M, Paul J, Pettit S, Simunovic N, Srinathan S, Thorlund K, Worster A, Villar JC, Walsh M, Yusuf S, Chan MTV, Chan PLM, Choi GYS, Gin T, Lit LCW, Multi PC, Schünemann H, Vizza E, Agnes MB. An international prospective cohort study evaluating major vascular complications among patients undergoing noncardiac surgery: the VISION Pilot Study. Open Med 2011.
- Devereaux PJ, Goldman L, Yusuf S, Gilbert K, Leslie K, Guyatt GH. Surveillance and prevention of major perioperative ischemic cardiac events in patients undergoing noncardiac surgery: a review\r10.1503/cmaj.050316. CMAJ 2005;173: 779–788.
- 27. Devereaux PJ, Biccard BM, Sigamani A, Xavier D, Chan MT V., Srinathan SK, Walsh M, Abraham V, Pearse R, Wang CY, Sessler DI, Kurz A, Szczeklik W, Berwanger O, Villar JC, Malaga G, Garg AX, Chow CK, Ackland G, Patel A, Borges FK, Belley-Cote EP, Duceppe E, Spence J, Tandon V, Williams C, Sapsford RJ, Polanczyk CA, Tiboni M, Alonso-Coello P. Association of postoperative high-sensitivity troponin levels with myocardial injury and 30-day mortality among patients undergoing noncardiac surgery. JAMA 2017;317:1642.
- 28. Sessler DI, Conen D, Leslie K, Yusuf S, Popova E, Graham M, Kurz A, Villar JC, Mrkobrada M, Sigamani A, Biccard BM, Meyhoff CS, Parlow JL, Guyatt G, Xavier D, Chan MT V., Kumar PA, Forget P, Malaga G, Fleischmann E, Amir M, Torres D, Wang CY, Paniagua P, Berwanger O, Srinathan S, Landoni G, Manach Y Le, Whitlock R, Lamy A. One-year results of a factorial randomized trial of aspirin versus placebo and clonidine versus placebo in patients having noncardiac surgery. Anesthesiology 2020;**132**:692–701.
- Yoshihisa A, Sato T, Kajimoto K, Sato N, Takeishi Y. Heterogeneous impact of body mass index on in-hospital mortality in acute heart failure syndromes: an analysis from the ATTEND Registry. *Eur Hear J Acute Cardiovasc Care* 2019;8:589–598.
- 30. Kajimoto K, Minami Y, Otsubo S, Sato N. Association of admission and discharge anemia status with outcomes in patients hospitalized for acute decompensated heart failure: differences between patients with preserved and reduced ejection fraction. Eur Hear J Acute Cardiovasc Care 2019;8:606–614.
- 31. Shen JT, Xu M, Wu Y, Wen SH, Li X, Zhao BC, Huang WQ. Association of preoperative troponin levels with major adverse cardiac events and mortality after

noncardiac surgery: A systematic review and meta-analysis. *Eur J Anaesthesiol* 2018;**35**:815–824.

- 32. Thomas S, Borges F, Bhandari M, Beer J De, Urrútia Cuchí G, Adili A, Winemaker M, Avram V, Chan MTV, Lamas C, Cruz P, Aguilera X, Garutti I, Alonso-Coello P, Villar JC, Jacka M, Wang CY, Berwanger O, Chow C, Srinathan S, Pettit S, Heels-Ansdell D, Rubery P, Devereaux PJ, Thomas S, Walsh M, Tiboni M, Guyatt G, Heels-Ansdell D, Thorlund K. Association between myocardial injury and cardiovascular outcomes of orthopaedic surgery: a Vascular Events in Noncardiac Surgery Patients Cohort Evaluation (VISION) substudy. J Bone Joint Surg Am 2020;102:880–888.
- 33. Mangano DT, Browner WS, Hollenberg M, London MJ, Tubau JF, Tateo IM, Group S of perioperative ischemia research. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group. N Engl J Med 1990;**323**:1781–1788.
- 34. Devereaux PJ, Duceppe E, Guyatt G, Tandon V, Rodseth R, Biccard BM, Xavier D, Szczeklik W, Meyhoff CS, Vincent J, Franzosi MG, Srinathan SK, Erb J, Magloire P, Neary J, Rao M, Rahate PV, Chaudhry NK, Mayosi B, Nadal M de, Iglesias PP, Berwanger O, Villar JC, Botto F, Eikelboom JW, Sessler DI, Kearon C, Pettit S, Sharma M, Connolly SJ. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. *Lancet* 2018;**391**:2325–2334.
- 35. Du Fay De Lavallaz J, Puelacher C, Lurati Buse G, Bolliger D, Germanier D, Hidvegi R, Walter JE, Twerenbold R, Strebel I, Badertscher P, Sazgary L, Lampart A, Espinola J, Kindler C, Hammerer-Lercher A, Thambipillai S, Guerke L, Rentsch K, Buser A, Gualandro D, Jakob M, Mueller C. Daytime variation of perioperative myocardial injury in non-cardiac surgery and effect on outcome. *Heart* 2019;**105**:826–833
- 36. Botto F, Alonso-Coello P, Chan MTV, Villar JC, Xavier D, Srinathan SK, Guyatt G, Cruz P, Graham M, Wang CY, Berwanger O, Pearse RM, Biccard BM, Abraham V, Malaga G, Hillis GS, Rodseth RN, Cook D, Polanczyk CA, Szczeklik W, Sessler DI, Sheth T, Ackland GL, Leuwer M, Garg AX, Lemanach Y, Pettit S, Heels-Ansdell D, Luratibuse G, Walsh M. Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology 2014;**120**:564–578